Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | AXL mutant |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants with Solid Tumors | Terminated | USA | GBR | FRA | ESP | 0 |
| NCT01639508 | Phase II | Cabozantinib | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Recruiting | USA | 0 |
| NCT04655391 | Phase I | Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | Withdrawn | USA | 0 |